Bioxcel Therapeutics Plunges 12.03% on Q2 Loss, Revenue Drop

On August 12, 2025, Bioxcel Therapeutics experienced a significant drop of 12.03% in pre-market trading, reflecting a notable decline in investor sentiment.

Bioxcel Therapeutics reported a net loss of $19.2 million for the second quarter of 2025, marking a substantial financial setback. The company's net revenue from IGALMI® also saw a significant decrease, falling to $120 thousand from $1.1 million in the same period last year. This financial performance has likely contributed to the recent stock price decline.

Additionally, the company announced that topline data expected in the second half of 2025 is crucial for supporting its ongoing business strategies. This anticipation of future data releases may have influenced investor decisions, leading to the pre-market drop.